Gemcitabine Hydrochloride Clinical Trials

• Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00262860 - Active, not recruiting
  Lymphoma
  
• Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00268242 - Recruiting
  Adult Acute Erythroid Leukemia; Adult Acute Monoblastic and Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia
  
• Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00244933 - Recruiting
  Breast Cancer
  
• Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering from Functional Dyspepsia
  ClinicalTrials.gov Identifier: NCT00112203 - Active, not recruiting
  Dyspepsia
  
• Long-term Safety and Efficacy of Itopride Hydrochloride in Patients Suffering from Functional Dyspepsia
  ClinicalTrials.gov Identifier: NCT00110968 - Active, not recruiting
  Dyspepsia
  
• Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
  ClinicalTrials.gov Identifier: NCT00234039 - Recruiting
  Recurrent Bladder Cancer; Stage 0 Bladder Cancer; Stage I Bladder Cancer; Transitional Cell Carcinoma of the Bladder
  
• EARTH 413: An Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer''s Disease (AD)
  ClinicalTrials.gov Identifier: NCT00230568 - Active, not recruiting
  Alzheimer''s Disease
  
• AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00219557 - Active, not recruiting
  Pancreatic Neoplasms
  
• Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Patients With Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00267020 - Active, not recruiting
  Pancreatic Neoplasm
  
• Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
  ClinicalTrials.gov Identifier: NCT00254904 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine
  ClinicalTrials.gov Identifier: NCT00294385 - Active, not recruiting
  Breast Cancer
  
• Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00480597 - Active, not recruiting
  Metastatic Breast Cancer
  
• A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults
  ClinicalTrials.gov Identifier: NCT00302458 - Recruiting
  Healthy
  
• Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00193362 - Active, not recruiting
  Lung Cancer
  
• GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer.
  ClinicalTrials.gov Identifier: NCT00358566 - Recruiting
  Adenocarcinoma
  
• Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With NSCLC
  ClinicalTrials.gov Identifier: NCT00441740 - Recruiting
  Non Small Cell Lung Cancer
  
• Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC
  ClinicalTrials.gov Identifier: NCT00442026 - Recruiting
  Non-Small-Cell Lung Cancer
  
• Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage
  ClinicalTrials.gov Identifier: NCT00226096 - Active, not recruiting
  CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
  
• Adjuvant Gemcitabine Plus Oxaliplatin vs. Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC
  ClinicalTrials.gov Identifier: NCT00452881 - Recruiting
  Lung Cancer
  
• A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00002318 - Active, not recruiting
  Sarcoma, Kaposi; HIV Infections
  
• Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00191139 - Active, not recruiting
  Carcinoma, Non Small Cell Lung
  
• Pilot Study Using Neoadjuvant Chemo-Radiotherapy and Tarceva for Potentially Resectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00216307 - Not yet recruiting
  adenocarcinoma of the pancreas
  
• Randomized Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
  ClinicalTrials.gov Identifier: NCT00471146 - Recruiting
  Carcinoma,Pancreatic Ductal
  
• Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotnib Followed of Capecitabine
  ClinicalTrials.gov Identifier: NCT00440167 - Recruiting
  Advanced; Pancreatic Cancer
  
• Hormone Therapy With LY353381 Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00003669 - Active, not recruiting
  stage IV endometrial cancer; recurrent endometrial cancer
  
• Effect of Affective Content on Drug Induced Amnesia of Episodic Memory
  ClinicalTrials.gov Identifier: NCT00142493 - Recruiting
  Memory Losses; Amnesia-Memory Loss
  
• Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer
  ClinicalTrials.gov Identifier: NCT00020644 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients with Advanced Transitional Cell Cancer of the Bladder
  ClinicalTrials.gov Identifier: NCT00136175 - Active, not recruiting
  Bladder Cancer
  
• Gemcitabine in Treating Neoplastic Meningitis in Patients With Leukemia, Lymphoma, or Solid Tumors
  ClinicalTrials.gov Identifier: NCT00052806 - Recruiting
  leptomeningeal metastases
  
• Study of Safety and Efficacy of Glufosfamide in Combination with Gemcitabine in Cancer
  ClinicalTrials.gov Identifier: NCT00102752 - Active, not recruiting
  Neoplasms; Pancreatic Neoplasms
  
• Intrathecal Gemcitabine in Treating Patients With Cancer and Neoplastic Meningitis
  ClinicalTrials.gov Identifier: NCT00039143 - Recruiting
  leptomeningeal metastases
  
• Alimta (pemetrexed) plus Gemzar (gemcitabine) in metastatic breast cancer patients after receiving Taxane therapy.
  ClinicalTrials.gov Identifier: NCT00063570 - Active, not recruiting
  Breast Cancer
  
• Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00027989 - Active, not recruiting
  stage IV breast cancer
  
• Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00100789 - Active, not recruiting
  Head and Neck Cancer
  
• Gemcitabine/Cisplatin Vs Gemcitabine/Epirubicin for NSCLC
  ClinicalTrials.gov Identifier: NCT00154739 - Recruiting
  Non-small cell lung cancer
  
• Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Docetaxel for NSCLC
  ClinicalTrials.gov Identifier: NCT00173888 - Recruiting
  Non-Small Cell Lung Cancer
  
• Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
  ClinicalTrials.gov Identifier: NCT00068549 - Active, not recruiting
  Cervical Cancer
  
• Hormone Therapy With LY353381 Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00003670 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer; stage IV ovarian epithelial cancer
  
• Trial Comparing Cisplatin With or Without Gemcitabine in Patients with Carcinoma of Unknown Primary
  ClinicalTrials.gov Identifier: NCT00126269 - Recruiting
  Carcinoma
  
• Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel
  ClinicalTrials.gov Identifier: NCT00003540 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Gemcitabine, Oxaliplatin in Combination with Bevacizumab in Patients with Hepatocellular Carcinoma
  ClinicalTrials.gov Identifier: NCT00142467 - Active, not recruiting
  Hepatocellular Carcinoma
  
• Gemcitabine and Capecitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Gallbladder Cancer or Cholangiocarcinoma
  ClinicalTrials.gov Identifier: NCT00033540 - Active, not recruiting
  extrahepatic bile duct cancer; Gallbladder Cancer
  
• Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
  ClinicalTrials.gov Identifier: NCT00012220 - Active, not recruiting
  adenocarcinoma of the pancreas; stage IVB pancreatic cancer
  
• 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00077415 - Active, not recruiting
  Non-small cell lung cancer
  
• Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00054288 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00006007 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome
  ClinicalTrials.gov Identifier: NCT00069550 - Recruiting
  Rett Syndrome
  
• Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004090 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00007917 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
  ClinicalTrials.gov Identifier: NCT00293176 - Active, not recruiting
  Memory Loss
  
• Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
  ClinicalTrials.gov Identifier: NCT00006453 - Active, not recruiting
  recurrent ovarian epithelial cancer
  
• Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00064207 - Active, not recruiting
  adenocarcinoma of the pancreas; stage I pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer
  
• Phase I/II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients with Advanced Stages Hodgkin''s Lymphoma
  ClinicalTrials.gov Identifier: NCT00147875 - Active, not recruiting
  Hodgkin''s Disease
  
• Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00079352 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• SU5416 Combined with Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00005996 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Phase I Study of Gemcitabine to Treat Cancer Spread to the Meninges
  ClinicalTrials.gov Identifier: NCT00048243 - Recruiting
  Meningeal Neoplasms
  
• Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
  ClinicalTrials.gov Identifier: NCT00003723 - Active, not recruiting
  advanced malignant mesothelioma; sarcomatous mesothelioma; epithelial mesothelioma
  
• Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00024427 - Active, not recruiting
  adenocarcinoma of the pancreas; Drug Toxicity; Pancreatic Cancer
  
• Gemcitabine in Treating Elderly Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005614 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Pemetrexed Disodium and Gemcitabine in Treating Patients With Malignant Mesothelioma
  ClinicalTrials.gov Identifier: NCT00060190 - Active, not recruiting
  advanced malignant mesothelioma; epithelial mesothelioma; sarcomatous mesothelioma
  
• Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00021346 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Comparison of Cisplatin Combined With Either Paclitaxel or Gemcitabine in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
  ClinicalTrials.gov Identifier: NCT00057928 - Active, not recruiting
  recurrent cervical cancer; stage IVB cervical cancer
  
• Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00022633 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00113256 - Recruiting
  Pancreatic Cancer
  
• A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH
  ClinicalTrials.gov Identifier: NCT00510406 - Active, not recruiting
  Lower Urinary Tract Symptoms; Prostatic Hyperplasia
  
• Gemcitabine, Docetaxel, and Capecitabine in Treating Patients with Cancer of Unknown Primary Origin
  ClinicalTrials.gov Identifier: NCT00119314 - Active, not recruiting
  newly diagnosed carcinoma of unknown primary; recurrent carcinoma of unknown primary
  
• Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00053209 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00031837 - Active, not recruiting
  adenocarcinoma of the pancreas; Pancreatic Cancer; Quality of Life; Thromboembolism
  
• Sorafenib and Gemcitabine in Treating Patients With Recurrent or Refractory Ovarian Cancer or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00096395 - Active, not recruiting
  peritoneal cavity cancer; recurrent ovarian epithelial cancer
  
• ABI-007 and Gemcitabine in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00110084 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer
  
• Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
  ClinicalTrials.gov Identifier: NCT00059852 - Active, not recruiting
  Male Breast Cancer; recurrent breast cancer; stage IV breast cancer
  
• ARQ 501 in Combination with Gemcitabine in Subjects with Cancer
  ClinicalTrials.gov Identifier: NCT00102700 - Active, not recruiting
  Pancreatic Cancer; Adenocarcinoma
  
• Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004095 - Active, not recruiting
  Bladder Cancer; Breast Cancer; Colorectal Cancer; kidney tumor; Lung Cancer; Pancreatic Cancer
  
• A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00504192 - Recruiting
  Advanced Biliary Tract Adenocarcinoma; Gemcitabine; Oxaliplatin; Combination Chemotherapy; Efficacy
  
• Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00042965 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003928 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00201760 - Recruiting
  Breast Cancer
  
• Gemcitabine and Docetaxel to Treat Bone and Soft Tissue Cancers
  ClinicalTrials.gov Identifier: NCT00070772 - Recruiting
  Osteosarcoma; Sarcoma, Ewing's; Chondrosarcoma
  
• Gemcitabine With or Without Radiation Therapy in Treating Patients with Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00057876 - Active, not recruiting
  stage III pancreatic cancer; adenocarcinoma of the pancreas
  
• Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00096070 - Active, not recruiting
  adenocarcinoma of the pancreas; stage II pancreatic cancer; stage III pancreatic cancer
  
• Study of the Combination of MDX-060 With Gemcitabine, MDX-060 Combined With Dexamethasone, and Gemcitabine Alone in Hodgkin's Disease
  ClinicalTrials.gov Identifier: NCT00284804 - Recruiting
  Hodgkin's Disease
  
• Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00068432 - Active, not recruiting
  recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00114244 - Active, not recruiting
  recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
  ClinicalTrials.gov Identifier: NCT00006028 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00006117 - Active, not recruiting
  stage III pancreatic cancer; stage IV pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00005829 - Active, not recruiting
  refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
  
• Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
  ClinicalTrials.gov Identifier: NCT00017186 - Active, not recruiting
  localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma
  
• Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00087802 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00064064 - Active, not recruiting
  recurrent non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00005093 - Active, not recruiting
  stage IIIA non-small cell lung cancer; stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; ...
  
• Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00073905 - Active, not recruiting
  adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer; Pain
  
• An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
  ClinicalTrials.gov Identifier: NCT00576173 - Active, not recruiting
  Pain
  
• Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00103051 - Active, not recruiting
  stage IIIA non-small cell lung cancer
  
• Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00006462 - Active, not recruiting
  recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia
  
• Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00004066 - Active, not recruiting
  adult soft tissue sarcoma; ovarian sarcoma; small intestine cancer; uterine sarcoma
  
• Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin,in Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00564720 - Recruiting
  Pancreatic Cancer
  
• Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
  ClinicalTrials.gov Identifier: NCT00159471 - Recruiting
  Pancreatic Cancer
  
• Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
  ClinicalTrials.gov Identifier: NCT00151034 - Active, not recruiting
  Advanced Urothelial Cancer
  
• Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00003264 - Active, not recruiting
  Salivary Gland Cancer; lip and oral cavity cancer; Head and Neck Cancer; Oropharyngeal Cancer
  
• Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00006118 - Active, not recruiting
  stage III bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder